PEGYLATED INTERFERON LAMBDA FOR ORAL ADMINISTRATION, AND METHOD FOR PRODUCING SAME

The group of inventions relates to medicine and more particularly to infectious diseases, and to pharmacology, the pharmaceutical industry and biotechnology, and is in the form of pegylated interferon lambda which exhibits antiviral activity with respect to hepatotropic viruses, characterised in that the oral bioavailability thereof is at least 10%, which provides for a high concentration thereof in the liver, bypassing systemic circulation, reduces systemic side effects, and increases treatment compliance. The invention also relates to a method for producing same which involves irradiating a solution of polyethylene glycol having a molecular mass of approximately 400 to approximately 5,000 Da with ionising radiation in a dose from 1 to 5 mrad, mixing the resulting solution with a solution of interferon lambda, freezing and cooling the resulting mixture to a temperature of -10°С and lower, and irradiating the frozen and cooled mixture with ionizing radiation in a dose from 0.1 to 0.5 mrad.